Compare Global E Online Ltd (GLBE) vs IDEXX Laboratories, Inc. (IDXX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Global E Online Ltd vs IDEXX Laboratories, Inc. — how do they compare? Global E Online Ltd trades at $41 (market cap $6.87B), while IDEXX Laboratories, Inc. trades at $573.33 (market cap $46.22B). The key difference: IDEXX Laboratories, Inc. is far larger — about 6.7× Global E Online Ltd's market cap, and Global E Online Ltd is trading nearer its 52-week high, IDEXX Laboratories, Inc. nearer its low. Which is the better fit depends on your goals.
| GLBE | IDXX | |
|---|---|---|
Market Cap | $6.87B | $46.22B |
Sector | Technology | Health |
52-Week High | $42.32 | $766.68 |
52-Week Low | $27.54 | $526.44 |
Enterprise Value | $6.34B | $47.12B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
GLBE trades at $39.76, down 3.38% on the day, with a bullish technical signal from moving averages and strong analyst support. The company reported Q2 2026 earnings that beat expectations, with revenue up 39% year-over-year and an adjusted EBITDA margin expansion to 20.9%. Recent news highlights the acquisition of Passport to enhance logistics capabilities and a $500 million share repurchase program authorization.
The outlook is positive, with 100% buy ratings from analysts and a consensus price target of $44.75 implying 12.5% upside. Key opportunities include robust revenue growth and margin expansion, while risks involve high valuation multiples and insider selling activity. The stock's trajectory hinges on continued execution of its global e-commerce enablement strategy.
IDEXX Laboratories (IDXX) trades at $571.44, down 4.08% over the past day, amid a mixed technical and strong fundamental backdrop. The stock shows a bullish trend in moving averages but overbought RSI readings near 73. Recent Q2 2026 earnings beat expectations with 9% organic revenue growth, and the company raised full-year EPS guidance. Profitability remains robust with a 25.03% net income margin and 74.21% ROE.
The outlook is positive given strong earnings momentum, high analyst buy ratings, and a consensus price target of $683.33 implying ~20% upside. Risks include premium valuation multiples and potential market volatility. The stock presents a growth opportunity supported by durable competitive advantages in veterinary diagnostics.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Global E Online Ltd
Global-e provides a platform for cross-border e-commerce, helping retailers increase international sales by localizing the shopping experience for consumers in over 200 destinations worldwide.
Read more on GLBE →About IDEXX Laboratories, Inc.
Idexx Laboratories primarily develops, manufactures, and distributes diagnostic products, equipment, and services for pets and livestock. Its key product lines include single-use canine and feline test kits that veterinarians can employ in the office, benchtop chemistry and hematology analyzers for test-panel analysis on-site, reference lab services, and tests to detect and manage disease in livestock. The firm also offers vet practice management software and consulting services to animal hospitals. Idexx gets about 38% of its revenue from outside the United States.
Read more on IDXX →
